ArticleJournal of immunology research2017
CD80 Expressed by CD8
Article in Journal of immunology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 40 citations in OpenAlex.
- A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.Haematologica · 2026Article
- Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy.Translational oncology · 2025Review
- Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report.Frontiers in immunology · 2025Article
- Prospects for the application of pathological response rate in neoadjuvant therapy for gastric cancer.Frontiers in oncology · 2025Review
- PGM5-AS1 Promotes Progression of Diffuse Large B-Cell Lymphoma and Immune Escape by Regulating miR-503-5p.Journal of inflammation research · 2024Article
- Immunohistochemical study of the expressed cluster differentiation markers proteins type 20 and 56 in breast tissues from a group of Iraqi patients with breast cancers.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Review
- Gut Microbiota and Liver Transplantation: Immune Mechanisms behind the Rejection.Biomedicines · 2023Review
- PD-L1's Role in Preventing Alloreactive T Cell Responses Following Hematopoietic and Organ Transplant.Cells · 2023Review
- The Role of Microbiota in Liver Transplantation and Liver Transplantation-Related Biliary Complications.International journal of molecular sciences · 2023Review
- Evaluation of Programmed Death - Ligand 1 (Pd-L1) Expression in Head and Neck Squamous Cell Carcinoma.Iranian journal of pathology · 2023Article
- GNAI2 Is a Risk Factor for Gastric Cancer: Study of Tumor Microenvironment (TME) and Establishment of Immune Risk Score (IRS).Oxidative medicine and cellular longevity · 2022Article
- Predictive and Prognostic Roles of Gut Microbial Variation in Liver Transplant.Frontiers in medicine · 2022Review
- Structural Analysis of SARS-CoV-2 ORF8 Protein: Pathogenic and Therapeutic Implications.Frontiers in genetics · 2021Review
- Apoptotic Donor Cells in Transplantation.Frontiers in immunology · 2021Review
- PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.Theranostics · 2021Article
- Article
- Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer.BMJ case reports · 2020Article
- Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor cells are capable of limiting antitumor CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.